Marijuana is mainstream. According to Marijuana Business Daily, almost 60 percent of Americans live in a state where some form of it is legal. Twenty-eight states have adopted reform laws, and it is one of the few political issues that seem to unite both Republicans and Democrats. (Well, sort of. Attorney General Jeff Sessions continues to wage an almost solitary war against legalization, but that’s another story.) I can’t walk into my local grocery store without seeing a glossy special edition of Newsweek, Time, National Geographic, or some other legacy news magazine dedicated to chronicling the marijuana revolution on sale in the checkout line. Yet, amidst vivid pictures of veterans protesting for the right to use medical marijuana, news releases of celebrities lending their names to emerging cannabis companies, and in-depth stories of the “green rush” and marijuana millionaires, a sleeping giant is awakening that very well may overtake the global cannabis economy.
I’m talking about hemp.
Specifically, I’m talking about hemp as a natural
Yet, despite all of these historic and new developments, hemp for health care is poised to be the economic powerhouse.
This is because of the unique and beneficial way that specialized compounds found in cannabis, called cannabinoids, interact with the human body.
The terms “hemp” and “marijuana” are mostly misleading. Both are the plant cannabis
Hemp is generally grown for its abundance of cannabidiol. Better known as CBD, this cannabinoid is not psychoactive and is responsible for a majority of the medical benefits associated with cannabis. Because of its almost ubiquitous health properties, even listing the medical issues for which it appears to offer benefits comes off as a snake oil medicine advertisement. Yet for over a decade, numerous studies have been written in peer-reviewed publications about CBD’s role in reducing pain, helping to relieve anxiety and PTSD, reducing seizures, as an anti-inflammation agent, and as neuroprotection that can aid victims of concussion, stroke, and even Alzheimer’s. Multiple studies have even confirmed that it reduces certain cancer cells. Big Pharma is rapidly developing CBD-based medication. Even the U.S. government holds a patent—number 6,630,507—on the use of non-psychoactive cannabinoids, such as CBD, to protect and insulate the brain from damage or degeneration.
Because of the enormous role that CBD plays in health, an entire industry has emerged to deliver CBD to people in the form of tinctures, vaping oils, topical applications, oral solutions, and in food and drink products. And although CBD can be derived from marijuana, its economic impact from this source is limited by marijuana’s federal illegal status preventing, among other things, interstate (and international) commerce. However, hemp is legal at the federal level. (This is an oversimplification: hemp’s legal status is complex, rapidly evolving, and in some respects “gray.” A large part of my practice involves advising my hemp and CBD business clients on how to stay on the correct side of the law.)
Being federally legal, hemp is not constrained by the same restrictions imposed on marijuana. This means that hemp-derived CBD can be transported, used, and sold across state and national borders. Numerous interesting legal issues are emerging from this sector, from federal regulatory oversight to banking and finance to marketing and labeling and quality control. But it is clear that hemp, marijuana’s relatively unfettered sibling, is poised to overtake the health industry, both in the U.S. and internationally.